- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07702266
Primary Parkinsonian Pain: Clinical Association and Phenotype (PHENOPAIN)
Among the different types of pain observed in Parkinson's disease, primary parkinsonian pain (PPP) is the most severe, the most difficult to treat, but also the least well characterized and the hardest to describe, not only by patients but also by neurologists. Consequently, PPP remains difficult to identify, even for clinicians with expertise in Parkinson's disease.
Nevertheless, patients with Parkinson's disease who experience PPP appear to exhibit certain demographic and clinical characteristics that may help distinguish them from other patients, including a poorer motor response to levodopa, a stronger association with sleep disturbances, and cognitive and behavioral features such as impulse control disorders (ICDs). PPP may therefore be associated with a specific disease phenotype supported by distinct pathophysiological mechanisms.
Recently, a disease progression model proposed the existence of a "Brain-First" subtype (characterized by disease onset in the brainstem) and a "Body-First" subtype (characterized by disease onset in the gastrointestinal system). Several clinical markers appear to distinguish these subtypes, notably the presence of REM sleep behavior disorder (RBD), which has been associated with the Body-First phenotype.
The association between PPP and RBD, as well as between PPP and the Body-First subtype, has never been investigated. We hypothesize that PPP may be associated with several clinical markers of the Body-First phenotype. Identifying such associations could facilitate the routine clinical diagnosis of PPP and, consequently, improve its management, which remains inadequate at present.
The primary objective is to assess the proportion of patients with primary parkinsonian pain according to the presence of probable RBD in Parkinson's disease.
This prospective, cross-sectional, non-interventional category 3 study (RIPH 3) will be conducted in 300 patients. Patients contacted through the France Parkinson Association and interested in participating in the study will be able to access the online questionnaire via a QR code or a web link. Completion of the questionnaire is expected to take no more than 15 minutes. This self-administered questionnaire will include collection of general data (age, sex, disease duration, initial motor symptoms, side of symptom onset predominance, and comorbidities), assessments of pain, migraine, sleep, constipation, olfaction, anxiety and depression and impulse control disorders.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Lise Laclautre
- Numéro de téléphone: +33473754963
- E-mail: promo_interne_drci@chu-clermontferrand.fr
Sauvegarde des contacts de l'étude
- Nom: Lise Laclautre
- E-mail: promo_interne_drci@chu-clermontferrand.fr
Lieux d'étude
-
-
-
Clermont-Ferrand, France
- CHU clermont-ferrand
-
Chercheur principal:
- Ana MARQUES
-
Contact:
- Lise Laclautre
- Numéro de téléphone: +33473754963
- E-mail: promo_interne_drci@chu-clermontferrand.fr
-
Contact:
- Lise Laclautre
- E-mail: promo_interne_drci@chu-clermontferrand.fr
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Age ≥ 18 years.
- French-speaking.
- Diagnosis of Parkinson's disease confirmed by a neurologist.
Exclusion Criteria:
- Atypical parkinsonian syndrome.
- Patients under legal protection (guardianship, curatorship, or legal safeguard measures).
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Parkinsonian patients
Patients with a diagnosis of Parkinson's disease confirmed by a neurologist
|
Completion of the questionnaire is expected to take no more than 15 minutes.
This self-administered questionnaire will include collection of general data (age, sex, disease duration, initial motor symptoms, side of symptom onset predominance, and comorbidities), assessments of pain, migraine, sleep, constipation, olfaction, anxiety and depression and impulse control disorders.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Presence of primary parkinsonian pain according to the 3PDQ questionnaire
Délai: at day 0
|
This self-questionnaire is completed by the patient during the inclusion visit
|
at day 0
|
|
Probable REM sleep behavior disorder (RBD), as identified using the RBD-1Q (REM Sleep Behavior Disorder Single-Question Screen).
Délai: at day 0
|
This self-questionnaire is completed by the patient during the inclusion visit
|
at day 0
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Presence of anosmia
Délai: at day 0
|
Self-reported olfactory dysfunction
|
at day 0
|
|
Presence of constipation
Délai: at day 0
|
Self-reported constipation dysfunction
|
at day 0
|
|
Presence of impulsive control disorders according the QUIP-Anytime During PD-Short (Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease)
Délai: at day 0
|
This self-questionnaire is completed by the patient during the inclusion visit
|
at day 0
|
|
Presence of Anxiety and/or depression according the HADs (Hospital Anxiety and Depression scale)
Délai: at day 0
|
This self-questionnaire is completed by the patient during the inclusion visit
|
at day 0
|
|
Prsence of RBD according the RBD SQ (RBD-Screening Questionnaire)
Délai: at day 0
|
This self-questionnaire is completed by the patient during the inclusion visit
|
at day 0
|
|
Pain intensity according an EVA scale
Délai: at day 0
|
patients will evaluate their pain with an EVA scale at inclusion visit
|
at day 0
|
|
Presence of comorbidities
Délai: at day 0
|
Patients will report if they had comorbidities such as diabete or osteoarticular disorders.
|
at day 0
|
|
presence of migraines
Délai: at day 0
|
patient will report if he had migraines
|
at day 0
|
|
Current antiparkinsonian and analgesic treatments
Délai: at day 0
|
Patient will report his current antiparkinsonian and analgesic treatments
|
at day 0
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Synucleinopathies
- Manifestations neurologiques
- Maladies du cerveau
- Maladies du système nerveux central
- Maladies du système nerveux
- Maladies neurodégénératives
- Troubles du mouvement
- Troubles parkinsoniens
- Maladies des noyaux gris centraux
- Conditions pathologiques, signes et symptômes
- Signes et symptômes
- La douleur
- Maladie de Parkinson
Autres numéros d'identification d'étude
- RNI 2026 MARQUES
- 2026-A01046-45 (Identificateur de registre: n° IDRCB)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .